Log In
Print
BCIQ
Print
Print this Print this
 

Namenda XR, memantine

  Manage Alerts
Collapse Summary General Information
Company Merz GmbH & Co. KGaA
DescriptionOnce-daily extended release formulation of memantine
Molecular Target
Mechanism of ActionNMDA receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat moderate to severe Alzheimer's disease (AD)
Regulatory Designation

Partner

Actavis plc


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today